Trump Slaps 50% Tariffs on Iran Arms Suppliers While Pharma Companies Get Sweetheart Deals

President Trump unveiled another round of tariffs on Wednesday, threatening 50% duties on any nation supplying weapons to Iran. The announcement came via Truth Social as a two-week ceasefire with Iran began, with Trump declaring "There will be no exclusions or exemptions!"

The move appears aimed at Russia and China, both of which maintain complex supply chain networks that could fall under the policy. Stock futures barely budged at the news, suggesting markets have grown numb to Trump's tariff threats or skeptical they'll be enforced as written.

Pharma Tariffs: All Bark, No Bite

The Iran weapons tariff came alongside Trump's Thursday announcement of a "100%" tariff on patented pharmaceuticals. But the White House immediately undercut its own tough talk by carving out exemptions so broad that few, if any, companies will actually pay the rate.

Companies can secure a 0% tariff rate by committing to build new US facilities by the end of Trump's term and signing agreements for Most-Favored-Nation drug pricing. Europe, Japan, South Korea, Switzerland, and the United Kingdom all got blanket exemptions through existing trade deals. Major pharmaceutical companies like AstraZeneca have already announced compliance deals with the government.

A senior administration official admitted to reporters that "the lion's share" of companies will qualify for the lower rates, meaning the 100% headline is pure theater. Companies have four to six months to comply, plenty of time to cut deals with an administration eager to claim credit for new facilities while letting corporations off the hook.

Metal Tariffs Get More Expensive Through Enforcement Changes

While Trump kept steel, aluminum, and copper tariffs at 50%, his administration changed how those tariffs are enforced in ways likely to increase what importers actually pay. Instead of relying on what importers declare, the government will now base duties on US spot market prices.

A senior administration official told reporters the change targets companies trying to "artificially create too low a price and try to fool us with the tariff you're paying." The official acknowledged this will mean higher tariff revenue for the government, admitting "we did not receive the tariff revenue we expected" under the previous system.

The White House also announced that goods containing less than 15% metal content are now exempt from metal tariffs entirely, while products with "substantial" metal content will pay a standard 25% rate. The administration framed this as simplifying paperwork for items like dental floss dispensers with small metal picks versus washing machines with significant metal components.

The $160 Billion Tariff Refund Mess

While Trump piles on new tariffs, his administration is simultaneously building a system to repay more than $160 billion in illegal tariff costs paid under the International Emergency Economic Powers Act. The Supreme Court struck down those IEEPA tariffs, and now more than 25,000 importers including Costco and FedEx have requested refunds.

The refund process highlights the chaos and legal vulnerability of Trump's tariff-by-executive-order approach. Businesses are navigating overlapping trade shocks from overturned tariffs to soaring energy costs from Middle East conflicts, with no clear sense of what rules will survive legal challenges or Trump's next Truth Social post.

Selective Enforcement and Corporate Favoritism

The pharmaceutical tariff carveouts expose how Trump's tariff regime operates: threaten dramatic action, then quietly exempt favored industries and countries while claiming victory. Companies that can afford lobbyists and facility announcements get 0% rates. Smaller importers without political connections pay full freight.

The Iran weapons tariff, by contrast, offers "no exclusions or exemptions" because it targets geopolitical adversaries rather than corporate donors. Whether the administration will actually enforce it against complex supply chains involving Russia and China remains to be seen. Trump's track record suggests tough talk followed by selective application based on political convenience.

Swiss pharmaceutical association Interpharma warned that Trump's tariff threats "threaten global production, supply chains, and ultimately will harm patients," according to Reuters. But with most major companies already cutting deals for 0% rates, the real harm falls on anyone without the resources to navigate Trump's pay-to-play tariff system.

US Trade Representative Katherine Greer said the administration aims to "maintain stable trade relations with China" ahead of a Trump-Xi summit next month. That stability apparently means threatening tariffs on paper while offering sweetheart deals to corporations willing to announce facilities and sign pricing agreements, all while ordinary importers and consumers pay the price.